Presentation:

Understanding Patient Response to Treatment Before Entering the Clinic

Recent advancements in immunotherapy are shifting the way that cancer is treated. The development of immuno-oncology therapies is creating the need for programs tailored to subsets of patients who are most likely to respond positively to treatment. Predictive preclinical models and translational strategies are needed to understand which patient populations will benefit from treatment and identify biomarkers of response.

This presentation covers:

• Importance of the tumor microenvironment
• In vivo models and translational results
• PDX Case Study: Building Confidence in NSCLC Clinical Population
• Preclinical profiling of patient populations